Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laboratory Medicine for Society.

Clinical chemistry and laboratory medicine·2026
Same author

Application of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) as biomarkers in the clinical management of multiple sclerosis (NeuroFilMS): a protocol for an observational cohort study.

BMJ open·2026
Same author

Anterior open wedge high tibial osteotomy for slope correction as a successful method in PCL insufficiency-Radiological and clinical results of a cohort study.

Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA·2026
Same author

Age-Dependent z Scores and eGFR-Adjusted Reference Ranges for Neurofilament Light: A Practical Approach for Clinical Laboratories.

Clinical chemistry·2026
Same author

EFLM position statement on the proposed 2025/0404(COD) IVDR Amendment of Article 5.5.

Clinical chemistry and laboratory medicine·2026
Same author

Representation and performance of CE-marked and in-house <i>in vitro</i> diagnostic tests for routine laboratory parameters in external quality assessment programmes.

Clinical chemistry and laboratory medicine·2026

Related Experiment Video

Updated: Jun 8, 2026

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

Comparison of two different methods for CA19-9 antigen determination.

Martina Deinzer1, Ralf Faissner, Tobias Metzger

  • 1Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany. martina.deinzer@onkologikum-labor.de

Clinical Laboratory
|September 23, 2010
PubMed
Summary

The Access GI Monitor and AxSYM CA19-9 assays show comparable clinical accuracy for pancreatic cancer management, despite systematic variations. Both methods support decision-making in patient care.

More Related Videos

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Experiment Videos

Last Updated: Jun 8, 2026

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Area of Science:

  • Clinical Chemistry
  • Immunoassays
  • Tumor Markers

Background:

  • Investigating the clinical performance of the Access GI Monitor (Beckman Coulter) for CA19-9 antigen determination.
  • Comparing the Access GI Monitor with the established CA19-9 assay on the AxSYM system (Abbott).

Purpose of the Study:

  • To evaluate the clinical utility of a new CA19-9 assay.
  • To compare the performance of two automated immunoassay systems for CA19-9 quantification.

Main Methods:

  • 1,063 serum samples analyzed using Passing-Bablok and Bland Altman regression analyses.
  • ROC analysis performed on patient groups including pancreatic cancer, acute, and chronic inflammation.
  • Four pancreatic cancer patients monitored longitudinally for inter-method concordance.

Main Results:

  • Passing-Bablok analysis revealed systematic differences (R=0.93, slope=0.75).
  • Bland Altman analysis indicated scatter, particularly at lower concentrations.
  • High concordance (95.5%) and comparable ROC curves (0.73 vs. 0.76) observed in pancreatic disease patients.

Conclusions:

  • Significant systematic variations exist between the two CA19-9 methods.
  • Despite variations, both automated assays demonstrate comparable clinical accuracy.
  • The methods are applicable for supporting clinical decisions in pancreatic cancer management.